{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:59:29Z","timestamp":1783749569589,"version":"3.55.0"},"reference-count":28,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T00:00:00Z","timestamp":1358208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2013,6]]},"abstract":"<jats:sec>\n                    <jats:title>What's known on the subject? and What does the study add?<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            The use of a single, elevated\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            level to screen for prostate cancer is controversial given its reported low specificity and the questionable benefits of\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            screening on prostate cancer mortality. Current guidelines in the\n                            <jats:styled-content style=\"fixed-case\">USA<\/jats:styled-content>\n                            recommend against screening using a single\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            measurement. Previous studies suggest that using changes in\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            level over time, or\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            velocity, may improve the detection of prostate cancer and\/or aggressive disease; however, this is also controversial as other studies suggest\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            velocity does not improve detection and may further contribute to the overdetection of indolent prostate cancer.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Given the questions that remain regarding the use of the rate of change in\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            as a screening tool for prostate cancer because of previous conflicting studies, which to date have included small, highly selected populations, this study adds to the existing knowledge by assessing this question in general practice settings among a large, diverse population.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            To determine whether the rate of change in total serum prostate\u2010specific antigen (\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            ) levels accurately detects prostate cancer and to evaluate whether it adds any predictive value to a single measurement of serum\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            alone, in general practice settings.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            A retrospective cohort of 219\u2009388 community\u2010dwelling men, aged \u226545 years, enrolled in the Kaiser Permanente Southern California health plan, with no history of prostate cancer and at least three\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            measurements, were followed from 1\n                            <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>\n                            anuary 1998 to 31\n                            <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>\n                            ecember 2007, for the development of biopsy\u2010confirmed prostate cancer.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Annual percent changes in total serum\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            levels were estimated using linear mixed models.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            The accuracy of prostate cancer prediction was assessed for prostate cancer overall and for aggressive disease (\n                            <jats:styled-content style=\"fixed-case\">G<\/jats:styled-content>\n                            leason score \u22657) and compared with that of a single measure of\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            level using area under the receiver\u2010operating characteristic curves (\n                            <jats:styled-content style=\"fixed-case\">AUCs<\/jats:styled-content>\n                            ).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            The men in this cohort experienced a mean change of 2.9% in\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            levels per year and the rate of change in\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            increased modestly with age (\n                            <jats:italic>P<\/jats:italic>\n                            \u2009\u2264\u20090.001).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Annual percent changes in\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            accurately predicted the presence of prostate cancer (\n                            <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                            \u2009=\u20090.963) and aggressive disease (\n                            <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                            \u2009=\u20090.955) and had more predictive accuracy for aggressive disease than did a single measurement of\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            alone (\n                            <jats:styled-content style=\"fixed-case\">AUC<\/jats:styled-content>\n                            \u2009=\u20090.727).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            Longitudinal measures of\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            improve the accuracy of aggressive prostate cancer detection when compared with a single measurement of\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            alone.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Findings from this study provide insight into the usefulness of\n                            <jats:styled-content style=\"fixed-case\">PSA<\/jats:styled-content>\n                            velocity as a detection marker for aggressive prostate cancer.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2012.11651.x","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T09:32:29Z","timestamp":1358242349000},"page":"1245-1252","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Changes in serum prostate\u2010specific antigen levels and the identification of prostate cancer in a large managed care population"],"prefix":"10.1111","volume":"111","author":[{"given":"Lauren P.","family":"Wallner","sequence":"first","affiliation":[{"name":"Department of Research and Evaluation Kaiser Permanente Southern California  Pasadena USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley K.","family":"Frencher","sequence":"additional","affiliation":[{"name":"Department of Urology Yale University  New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin\u2010Wen Y.","family":"Hsu","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation Kaiser Permanente Southern California  Pasadena USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun R.","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation Kaiser Permanente Southern California  Pasadena USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Nichol","sequence":"additional","affiliation":[{"name":"School of Pharmacy University of Southern California  Los Angeles USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald K.","family":"Loo","sequence":"additional","affiliation":[{"name":"Department of Urology Southern California Permanente Medical Group  Downey CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Department of Research and Evaluation Kaiser Permanente Southern California  Pasadena USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,1,15]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810696"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810084"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67064-2"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj410"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.12.008"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2008.01.082"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032975"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.4.440"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20210"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-007-0119-x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.1490"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.07.047"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1685"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.05.029"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr028"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.08.156"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.07.093"},{"key":"e_1_2_8_19_1","volume-title":"SEER Summary Staging Manual \u2013 2000: Codes and Coding Instructions","author":"Young JLJRS","year":"2001"},{"key":"e_1_2_8_20_1","first-page":"125","article-title":"Classification of prostatic carcinomas","volume":"50","author":"Gleason DF","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.10.028"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2011.10900.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000132133.10470.bb"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21553"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.09.002"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.2990220105"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68543-6"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(94)80049-9"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80014-4"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2012.11651.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2012.11651.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T11:55:48Z","timestamp":1761738948000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2012.11651.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,15]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["10.1111\/j.1464-410X.2012.11651.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2012.11651.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,15]]},"assertion":[{"value":"2013-01-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}